Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Operating Expenses: 2017-2025

Historic Operating Expenses for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Sep 2025 value amounting to $142.7 million.

  • Crinetics Pharmaceuticals' Operating Expenses rose 62.57% to $142.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $479.4 million, marking a year-over-year increase of 55.74%. This contributed to the annual value of $339.9 million for FY2024, which is 49.98% up from last year.
  • As of Q3 2025, Crinetics Pharmaceuticals' Operating Expenses stood at $142.7 million, which was up 9.67% from $130.1 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Operating Expenses registered a high of $142.7 million during Q3 2025, and its lowest value of $22.9 million during Q1 2021.
  • Moreover, its 3-year median value for Operating Expenses was $83.2 million (2024), whereas its average is $86.5 million.
  • Data for Crinetics Pharmaceuticals' Operating Expenses shows a peak YoY spiked of 85.00% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Crinetics Pharmaceuticals' Operating Expenses stood at $26.1 million in 2021, then spiked by 85.00% to $48.3 million in 2022, then climbed by 29.82% to $62.7 million in 2023, then surged by 51.21% to $94.7 million in 2024, then spiked by 62.57% to $142.7 million in 2025.
  • Its Operating Expenses was $142.7 million in Q3 2025, compared to $130.1 million in Q2 2025 and $111.8 million in Q1 2025.